Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome?
- PMID:18234443
- DOI: 10.1016/j.ijrobp.2007.11.035
Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome?
Abstract
Background: The optimal interval between neoadjuvant chemoradiation therapy (CRT) and surgery in the treatment of patients with distal rectal cancer is controversial. The purpose of this study is to evaluate whether this interval has an impact on survival.
Methods and materials: Patients who underwent surgery after CRT were retrospectively reviewed. Patients with a sustained complete clinical response (cCR) 1 year after CRT were excluded from this study. Clinical and pathologic characteristics and overall and disease-free survival were compared between patients undergoing surgery 12 weeks or less from CRT and patients undergoing surgery longer than 12 weeks from CRT completion and between patients with a surgery delay caused by a suspected cCR and those with a delay for other reasons.
Results: Two hundred fifty patients underwent surgery, and 48.4% had CRT-to-surgery intervals of 12 weeks or less. There were no statistical differences in overall survival (86% vs. 81.6%) or disease-free survival rates (56.5% and 58.9%) between patients according to interval (< or =12 vs. >12 weeks). Patients with intervals of 12 weeks or less had significantly higher rates of Stage III disease (34% vs. 20%; p = 0.009). The delay in surgery was caused by a suspected cCR in 23 patients (interval, 48 +/- 10.3 weeks). Five-year overall and disease-free survival rates for this subset were 84.9% and 51.6%, not significantly different compared with the remaining group (84%; p = 0.96 and 57.8%; p = 0.76, respectively).
Conclusions: Delay in surgery for the evaluation of tumor response after neoadjuvant CRT is safe and does not negatively affect survival. These results support the hypothesis that shorter intervals may interrupt ongoing tumor necrosis.
Similar articles
- An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.Tulchinsky H, Shmueli E, Figer A, Klausner JM, Rabau M.Tulchinsky H, et al.Ann Surg Oncol. 2008 Oct;15(10):2661-7. doi: 10.1245/s10434-008-9892-3. Epub 2008 Apr 4.Ann Surg Oncol. 2008.PMID:18389322
- Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.Lim SB, Choi HS, Jeong SY, Kim DY, Jung KH, Hong YS, Chang HJ, Park JG.Lim SB, et al.Ann Surg. 2008 Aug;248(2):243-51. doi: 10.1097/SLA.0b013e31817fc2a0.Ann Surg. 2008.PMID:18650634
- Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer.Ceelen W, Boterberg T, Pattyn P, van Eijkeren M, Gillardin JM, Demetter P, Smeets P, Van Damme N, Monsaert E, Peeters M.Ceelen W, et al.Ann Surg Oncol. 2007 Feb;14(2):424-31. doi: 10.1245/s10434-006-9102-0. Epub 2006 Nov 10.Ann Surg Oncol. 2007.PMID:17096057
- Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified?Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J.Glynne-Jones R, et al.Dis Colon Rectum. 2008 Jan;51(1):10-9; discussion 19-20. doi: 10.1007/s10350-007-9080-8. Epub 2007 Nov 28.Dis Colon Rectum. 2008.PMID:18043968Review.
- Locally advanced rectal cancer: what is the evidence for induction chemoradiation?Glynne-Jones R, Harrison M.Glynne-Jones R, et al.Oncologist. 2007 Nov;12(11):1309-18. doi: 10.1634/theoncologist.12-11-1309.Oncologist. 2007.PMID:18055850Review.
Cited by
- Down-staging following neoadjuvant chemo-radiotherapy for locally advanced rectal cancer: Does timing of surgery really matter?Sirohi B, Barreto SG, Patkar S, Gupta A, DeSouza A, Talole S, Deodhar K, Shetty N, Engineer R, Goel M, Shrikhande SV.Sirohi B, et al.Indian J Med Paediatr Oncol. 2014 Oct;35(4):263-6. doi: 10.4103/0971-5851.144986.Indian J Med Paediatr Oncol. 2014.PMID:25538402Free PMC article.
- ACR appropriateness criteria® resectable rectal cancer.Jones WE 3rd, Thomas CR Jr, Herman JM, Abdel-Wahab M, Azad N, Blackstock W, Das P, Goodman KA, Hong TS, Jabbour SK, Konski AA, Koong AC, Rodriguez-Bigas M, Small W Jr, Zook J, Suh WW.Jones WE 3rd, et al.Radiat Oncol. 2012 Sep 24;7:161. doi: 10.1186/1748-717X-7-161.Radiat Oncol. 2012.PMID:23006527Free PMC article.
- Optimal Time Interval for Surgery After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer: Analysis of Health Insurance Review and Assessment Service Data.Kim MJ, Cho JS, Kim EM, Ko WA, Oh JH.Kim MJ, et al.Ann Coloproctol. 2018 Oct;34(5):241-247. doi: 10.3393/ac.2018.01.01. Epub 2018 Oct 31.Ann Coloproctol. 2018.PMID:30419721Free PMC article.
- Effect of Interval between Neoadjuvant Chemoradiotherapy and Surgery on Oncological Outcome for Rectal Cancer: A Systematic Review and Meta-Analysis.Wang XJ, Zheng ZR, Chi P, Lin HM, Lu XR, Huang Y.Wang XJ, et al.Gastroenterol Res Pract. 2016;2016:6756859. doi: 10.1155/2016/6756859. Epub 2016 Mar 30.Gastroenterol Res Pract. 2016.PMID:27190505Free PMC article.Review.
- Diffusion-weighted MRI in locally advanced rectal cancer : pathological response prediction after neo-adjuvant radiochemotherapy.Intven M, Reerink O, Philippens ME.Intven M, et al.Strahlenther Onkol. 2013 Feb;189(2):117-22. doi: 10.1007/s00066-012-0270-5. Epub 2012 Dec 19.Strahlenther Onkol. 2013.PMID:23283590Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials